ArticleBMC medical imaging2026
Incremental prognostic value of myocardial strain in patients with coronary slow flow.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAlthough coronary slow flow (CSF) was associated with adverse cardiac outcomes, the prognostic value of myocardial strain (MS) for major adverse cardiovascular events (MACEs) in CSF is not well established. We aimed to examine the longitudinal association between MS and MACEs in this population.
methodsMedical records from 336 patients with CSF (January 2019 to June 2022) were analyzed retrospectively. All patients underwent comprehensive echocardiography with MS quantified via speckle tracking echocardiography (STE), including left ventricular global longitudinal strain (LVGLS) and circumferential strain (LVGCS). MACEs were defined as the primary endpoint. Multivariable Cox regression analysis was performed to evaluate the association between MS and MACEs.
resultsDuring a median follow-up of 19 months (range: 6–51 months), MACEs occurred in 37.8% (127/336). LVGCS was independently associated with MACEs (HR = 1.794, 95% CI 1.307–2.462, P < 0.001) after adjusting for conventional risk factors and may provide incremental prognostic value beyond conventional risk factors (C statistics increased from 0.790 to 0.885; IDI = 0.172, P < 0.001; NRI = 0.790, P < 0.001).
conclusionsLVGCS was independently associated with MACEs in CSF patients. Adding LVGCS to conventional risk factors may provide incremental prognostic information, suggesting its potential utility for improving risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.